Significant antifracture efficacy of oral ibandronate in women with low bone mass

被引：0
|
作者：
Lorenc, R
Felsenberg, D
Stakkestad, JA
Gibride, J
Schimmer, RC
机构：
[1] Childrens Mem Inst, Warsaw, Poland
[2] Univ Klinikum Benjamin Franklin, Osteoporose Forsch Grp, Berlin, Germany
[3] CECOR AS, Haugesund, Norway
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：452 / 452
页数：1
相关论文
共 50 条
  • [1] Oral ibandronate provides significant antifracture efficacy in women with low bone mass
    Miller, PD
    Lorenc, R
    Harris, ST
    Stakkestad, JA
    Gilbride, J
    Schimmer, RC
    [J]. OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S108 - S109
  • [2] Significant antifracture benefit with ibandronate in postmenopausal women with high baseline bone turnover
    Epstein, S
    Rosen, CJ
    Mahoney, P
    Schimmer, RC
    Chesnut, CH
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S72 - S72
  • [3] Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
    Chesnut, CH
    Ettinger, MP
    Miller, PD
    Baylink, DJ
    Emkey, R
    Harris, ST
    Wasnich, RD
    Watts, NB
    Schimmer, RC
    Recker, RR
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (03) : 391 - 401
  • [4] THE ANTIFRACTURE EFFICACY OF IBANDRONATE: A COMPENDIUM OF EVIDENCE
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 182 - 183
  • [5] Efficacy and Safety of Monthly Oral Ibandronate in Postmenopausal Women with Low Bone Density.
    Bolognese, M. A.
    McClung, M. R.
    Sedarati, F.
    Recker, R. R.
    Miller, P. D.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S339 - S339
  • [6] Ibandronate-induced reduction of bone turnover marker predicts antifracture efficacy
    Miller, P. D.
    Blackburn, R.
    Grant, R.
    Recker, R. R.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S46 - S46
  • [7] Oral ibandronate produces significant antifracture efficacy when given intermittently with a between-dose interval of >2 months
    Felsenberg, D
    Halse, J
    Skag, A
    Gilbride, J
    Schimmer, RC
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 97 - 97
  • [8] Bone remodelling and antifracture efficacy of oral bisphosphonate therapy
    Papapoulos, Socrates E.
    [J]. BONE, 2007, 41 (05) : S32 - S32
  • [9] Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy
    Amling, Michael
    Kurth, Andreas
    [J]. WOMENS HEALTH, 2009, 5 (05) : 467 - 473
  • [10] Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate
    Paul D. Miller
    Pierre D. Delmas
    Hermann Huss
    Katie M. Patel
    Ralph C. Schimmer
    Silvano Adami
    Robert R. Recker
    [J]. Calcified Tissue International, 2010, 87 : 305 - 313
12345